Business Wire

THALES

10.9.2019 09:32:03 CEST | Business Wire | Press release

Share
Fintech innovator Treezor chooses Thales Cloud HSM to Uphelp secure Banking-as-a-Service

Thales today announced that Treezor, the leading banking-as-a-service platform in France, has deployed its SafeNet Data Protection On Demand solution to provide security across its entire payment chain, from tier one banks and neo-banks to crowdfunding organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005069/en/

As an electronic money issuer, Treezor is bound by a variety of data privacy regulations and requirements, including requirements from the French Regulator (ACPR), the Mastercard network and the European Union’s General Data Protection Regulation (GDPR). Treezor is required to implement strong data security controls to protect personal financial information and other sensitive data. After evaluating several providers, Treezor selected SafeNet Data Protection On Demand (DPoD) due to its ability to provide a cost-effective and easy-to-use cloud HSM service as a highly secure root of trust for cryptographic operations.

“Innovation is the lifeblood of how we operate, but it should never come at the expense of security or vice versa,” said Eric Lassus, CEO of Treezor . “Part of our ethos is to work extremely closely with our clients to understand their needs, which led to the creation of our payment platform using standard APIs. As a result, we need a solution that meets our security, management and commercial needs.”

Treezor, recently acquired by Societe Generale, was familiar with the security advantages of HSMs, but wanted to minimize investments and on-going overheads, so it began investigating cloud-based offerings. Taking advantage of the 30-day free evaluation offered by Thales for its cloud-based HSM solution, Treezor was impressed by the ease of use and the speed it was able to deploy its test environment. During the evaluation phase of SafeNet Data Protection On Demand, the ‘point-and-click’ ease of use convinced Treezor that SafeNet Cloud HSM On Demand service provided the best solution in terms of cost, security and ease of implementation.

With SafeNet Data Protection On Demand, Treezor benefits from:

  • Rapid deployment and easy integration – Cloud HSM services were up and running and integrated into their systems in minutes
  • Service Level Availability – Unlike other Cloud HSM services on the market, SafeNet Data Protection On Demand comes with a 99.95% SLA
  • Predictable costs – Pricing is provided in a predictable way with all costs like redundancy and back-up services inclusive, meaning no hidden charges for high availability

Treezor’s strategy has led to a dramatic growth in two years, from issuing 100,000 cards and €400,000 of transactions in 2017 to over 500,000 cards and €5 billion in 2018.

With the scalability of SafeNet Cloud HSM On Demand, alongside its separation of duties, Treezor can offer each customer their own dedicated HSM service, bringing them safety in the knowledge that their financial and other sensitive data is segregated and protected.

“Working in the financial sector, trust is an extremely high parameter with which companies are judged by customers,” Lassus continued. “We chose Thales because of its stellar reputation in security, the ease-of-use of the whole solution and the high SLAs it guarantees. It’s vital too that we’re able to give our customers a clear insight into costs and availability of our services. The transparency and reliability we’ve received with SafeNet Data Protection On Demand is ideal for our needs of offering services simply, secure and costs effectively across our entire payment chain, from traditional banks to the most innovative fintech companies.”

Todd Moore, vice president of encryption products for cloud protection and licensing activity at Thales said: “The financial industry is one of the most regulated in the world, so it can sometimes be tricky for some to find that balance between innovation and compliance. With SafeNet Data Protection on Demand, Treezor can offer innovative solutions across its payment platform, while ensuring a transparent and secure approach that satisfies both regulators and customers.”

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.

 

About Treezor

Founded in 2016 by Éric Lassus and Xavier Labouret, Treezor is a French Bank-as-a-Service platform covering the entire payment chain through API based solutions. The fintech is an approved electronic money issuer and a Mastercard principal member. As a young and innovative company, Treezor devotes a significant part of its resources to develop new technologies in the field of open banking to support the strategy and service deployment of its customers.

PLEASE VISIT
Thales Group
Digital Security
Download HD photos

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye